Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Seikagaku Corp.: Good US Sales Prop Up Business
May 29, 2006
- Eisai: Another Year of Record Sales and Profits
May 29, 2006
- Kirin: Pharma Division Posts 14.5% Growth in Sales
May 29, 2006
- Taisho: Pharma Sales Up 0.6%, Self-medication Sales Down 4.7%
May 29, 2006
- JT: New 3-Year Management Plan Aimed at Long-term Growth
May 29, 2006
- Shionogi: Royalties Prop Up Profits Despite Lower Sales
May 29, 2006
- Industry Should Oppose Unreasonable Proposals: New FPMAJ President
May 29, 2006
- Mr T. Korekane Appointed President: Ono
May 29, 2006
- So-net M3 Starts Trial Run of "Doctors Blog"
May 29, 2006
- Santen: Ethical Drug Sales Up Domestically and Overseas
May 29, 2006
- STATISTICS
May 29, 2006
- Meiji Seika: Sales of Ethical Drugs Up 6.2% to \94,353 Mil.
May 29, 2006
- Terumo and Yakult Honsha Codevelop Irinotecan DDS
May 29, 2006
- Meiji Seika Announces New Midterm Management Plan
May 29, 2006
- Usefulness of MD Studies Stressed at Mass Spectrometry Conference
May 29, 2006
- Kaken: Sales of Generics Up 39.5%
May 29, 2006
- Korosho to Set Up New Clinical Study Search System
May 29, 2006
- Kyorin: Domestic Market Drives Growth in Sales
May 29, 2006
- R&D NEWS IN BRIEF
May 29, 2006
- SURVEY 2 articles
May 29, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…